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INTRODUCTION
Degenerative dementia has become a serious health problem in 
Korea, as the prevalence of dementia is almost 10.0% in the popu-
lation above the age of 65 years. The management of dementia in 
Korea costs approximately 20 million Korean won (KRW) per 
person annually in 2015 [1]. Moreover, dementia imposes a psy-
chosocial burden on both patients and caregivers [2]. Thus, more 
effective risk evaluation and management for dementia could al-
leviate economic, psychological, and social problems [3]. For ex-
OBJECTIVES: Both cardiovascular health (CVH) and inflammation are associated with cognition, and inflammation is also 
associated with CVH. However, limited information has been reported on these factors in the Korean population. The objective 
of our study was to investigate the influence of inflammation on the association between CVH and cognition using a cross-sec-
tional design.
METHODS: Data were obtained from the Cardiovascular and Metabolic Diseases Etiology Research Center baseline study. 
Participants who completed fasting serum analysis, questionnaires, and cognitive function tests were included in the analysis, 
whereas those with a history of autoimmune disease were excluded. The CVH in Ambulatory Care Research Team health index 
metrics, including smoking, physical activity, healthy diet, obesity, history of hypertension, and diabetes, were used to assess 
CVH. Cognitive function was evaluated with the Korean version of the Mini-Mental State Estimation for Dementia Screening. 
Inflammatory status was assessed based on a high-sensitivity C-reactive protein (hs-CRP) test.
RESULTS: Among 2,622 total participants (mean age, 57.2 years; 1,792 women), 13%, 58%, and 29% had poor, intermediate, 
and ideal CVH, respectively. Logistic regression analysis demonstrated that CVH was significantly associated with cognitive 
function only in women. A stratified analysis showed that cognitive impairment due to CVH was not associated with hs-CRP 
levels. When the same analyses were conducted for each CVH component, the only component affecting the association was 
hypertension history in men.
CONCLUSIONS: CVH is not significantly associated with cognitive decline in the middle-aged Korean population. Inflamma-
tion did not play a significant modifying role in this relationship.
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ample, the early diagnosis of dementia reduces the cost of care for 
Alzheimer disease (AD) by US$100 billion annually in the United 
States [3].
The current treatments for AD are rivastigmine, donepezil, gal-
antamine, and memantine [4]. It has been revealed that an early 
diagnosis and treatment of AD improves the prognosis [3,5]. Un-
fortunately, the clinical diagnosis of AD is being made by positron 
emission tomography and cerebrospinal fluid studies, which are 
expensive or invasive, and only give information after AD has de-
veloped to some extent [4]. To start treatment of AD earlier, it is 
necessary to identify a biomarker that reflects the risk of AD [6]. 
Many previous studies have suggested that poor cardiovascular 
health (CVH) is significantly associated with low cognitive func-
tion and dementia [7,8]. A previous study conducted in France 
showed that higher CVH scores were associated with a lower risk 
of dementia and cognitive decline [8]. Additionally, levels of in-
flammatory markers such as high-sensitivity C-reactive protein 
(hs-CRP) are related to both CVH and cognitive function [9,10]. 
The Centers for Disease Control and Prevention and the Ameri-
can Heart Association have already proposed hs-CRP as a useful 
tool for determining cardiovascular disease risk [10]. C-reactive 
protein (CRP) could predict cardiovascular risk as much as lipid 
levels do [11]. A report has also stated that individuals who have 
high physical activity and consume a healthy diet show both low 
inflammatory levels and high CVH [12]. Inflammatory status is 
also associated with cognitive function [13]. CRP could therefore 
be a useful marker of memory and visuospatial impairment in el-
derly individuals [14]. The plasma level of CRP was found to be 
higher in patients with AD than in healthy controls [15]. Higher 
hs-CRP levels were also related to reduced cerebral microstruc-
tural integrity [16]. Consequently, inflammation could be consid-
ered a possible factor connecting CVH and cognitive impairment.
Previously, CVH scores were usually measured by the American 
Heart Association (AHA) Life’s Simple 7 tool [17]. However, no 
significant association was found between CVH and early cogni-
tive dysfunction in a Korean cohort based on the AHA Life’s Sim-
ple 7 tool [18]. The CANHEART model was developed to evaluate 
CVH in the Canadian population by the Canadian Community 
Health Survey, inspired by the AHA Life’s Simple 7 tool. It success-
fully predicted CVH risk in Canadian population. Furthermore, 
unlike the AHA Life’s Simple 7 tool, the CANHEART health in-
dex does not require laboratory testing, meaning that it is highly 
convenient and accessible for evaluating patients [19]. 
Therefore, we aimed to investigate the association between CVH 
and cognitive decline, and then to explore cognitive decline accord-
ing to hs-CRP levels and CVH to determine whether hs-CRP is 




The Cardiovascular and Metabolic Diseases Etiology Research 
Center (CMERC) study was conducted between 2013 and 2018 to 
investigate risk factors for cardiovascular and metabolic disease. The 
CMERC study enrolled participants meeting the following criteria: 
(1) aged 30 years to 64 years, (2) having an urban residence in 
Seoul or nearby, (3) able to articulate their own opinions, (4) no 
history of overt cardiovascular diseases (lifetime), or malignant 
cancer (within the previous 2 years), (5) no concurrent enrollment 
in other clinical trials, and (6) not pregnant at baseline. The details 
of the study are described elsewhere [20]. Cognitive function at 
age 50 years or older (n= 2,663) was evaluated with the Mini-Men-
tal State Examination (MMSE), which was administered to the 
entire cohort. Forty-one participants with lifetime autoimmune 
disease or with incomplete socio-demographic information, in-
cluding education, household income, or marital status, were ex-
cluded. Finally, a total of 2,622 participants were included in this 
analysis. 
Assessment of cardiovascular health and the 
cardiovascular risk score
We used the AHA Life’s Simple 7 tool (2010) and the Cardio-
vascular Health in Ambulatory Care Research Team (CANHEART) 
health index (2013) [19]. In the AHA Life’s Simple 7 tool, each of 
the 7 components was categorized as “poor,” “intermediate,” or 
“ideal” according to the AHA’s guidelines; details of the criteria 
applied to each component are described in Supplementary Ma-
terial 1. The CANHEART health index was developed to evaluate 
the Canadian population and references data from the Canadian 
Community Health Survey, a cross-sectional telephone survey of 
self-reported health status, determinants, and health service use 
by Canadian adults aged 20 years or older. Unlike the AHA Life’s 
Simple 7 tool, the CANHEART health index does not require a 
laboratory test. The CANHEART health index includes health 
behaviors such as smoking, physical activity, healthy diet, obesity, 
diabetes mellitus, and hypertension history [19]. We scored the 
sum of each component in both CVH indices, and all were equal-
ly weighted (AHA Life’s Simple 7 tool score: 0-7; CANHEART 
health index score: 0-6). 
Measurement of cognitive function
Cognitive function was tested with the Korean version of the 
Mini Mental State Examination for Dementia Screening (MMSE-
DS), administered by trained interviewers to participants aged at 
least 50 years. The MMSE-DS measures cognitive function using 
questions to evaluate various categories of cognitive function, in-
cluding time and place, orientation, registration, attention and 
calculation, memory recall, speaking, and visual construction. If 
any item had a missing value, the total MMSE-DS score was dis-
carded (n= 6). According to a previous validation study in Korea, 
the test showed excellent internal consistency and diagnostic ac-
curacy (area under the curve, 0.895 [0.880 to 0.911]) [21]. In this 
study, individuals with an MMSE-DS score below 24 were catego-
rized as having low cognitive function. 
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Measurement of the high-sensitivity C-reactive 
protein level as an indicator of inflammatory status 
Inflammatory status was assessed using 8-hour fasting morning 
blood plasma samples. Plasma levels of hs-CRP were analyzed with 
a turbid immunoassay (ADVIA1800 Auto Analyzer; Siemens Medical 
Solutions, Malvern, PA, USA). According to the manufacturer, the 
detection range for the hs-CRP assay is 0.01 mg/L to 1,000 mg/L, with 
a sensitivity of 0.2 mg/L (men: median, 0.64; interquartile range, 
0.40 to 1.36; women: median, 0.60; interquartile range, 0.34 to 1.18).
Covariates
During the baseline assessment, the participants were asked 
questions regarding demographic characteristics, socioeconomic 
status, medical/medication history, family history, and lifestyle 
factors (smoking, drinking, sleeping, physical activity, and food 
consumption) by a trained interviewer using a general question-
naire with a standardized protocol. Household income was classi-
fied into quartiles (< 24.0, 24.0 to < 34.6, 34.6 to < 49.0, and ≥ 49.0 
million KRW/yr). Education level was categorized into groups ac-
cording to the educational curriculum in Korea (elementary school 
or below, middle school, high school, college, or above). Marital 
status was classified as “never married,” “widowed,” “separated/di-
vorced,” or “married and living together.” Smoking and drinking 
were categorized as “never,” “past,” or “current.” Physical activity 
was assessed with a Korean version of the International Physical 
Activity Questionnaire-short form, which enquires about the fre-
quency of each of the following activities: walking, moderate-in-
tensity activity, and vigorous activity. The validity of the Korean 
version of the International Physical Activity Questionnaire-short 
form has been confirmed, but it has low reliability [22].
In this study, blood samples were collected after an 8-hour fast 
and transported on the registration date to the institution where 
Values are presented as mean±standard deviation or number (%). 
MMSE-DS, Mini-Mental State Examination-Dementia Screening; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; 
HbA1c, hemoglobin A1c; hs-CRP: high-sensitivity C-reactive protein.
1Participants walking at least 30 minutes per day were grouped into the regular physical activity group.
2Self-reported disease history.













   Non-drinker 670 (25.6) 645 (25.4) 25 (28.7) 0.460 
   Former drinker 126 (4.8) 124 (4.9) 2 (2.3) 
   Current drinker 1,826 (69.6) 1,766 (69.7) 60 (69.0) 
Regular physical activity1
   No 705 (26.9) 682 (26.9) 23 (26.4) 0.920 
   Yes 1,917 (73.1) 1,853 (73.1) 64 (73.6) 
Body mass index 24.0±2.9 24.0±2.9 24.3±2.6 0.360 
Ever had hypertension2
   No 2,018 (77.0) 1,955 (77.1) 63 (72.4) 0.310 
   Yes 604 (23.0) 580 (22.9) 24 (27.6) 
SBP (mmHg) 120.3±15.1 120.4±15.2 119.2±14.3 0.480 
DBP (mmHg) 76.6±9.6 76.6±9.6 74.7±8.3 0.060 
Ever had DM2
   No 2,438 (93.0) 2,359 (93.1) 79 (90.8) 0.420 
   Yes 184 (7.0) 176 (6.9) 8 (9.2) 
Fasting insulin (μIU/mL) 8.8±3.7 8.8±3.7 8.7±3.2 0.670 
Fasting glucose (mg/dL) 93.9±20.3 93.9±20.5 93.0±14.4 0.580 
HbA1c (%) 5.8±0.7 5.8±0.7 5.8±0.5 0.580 
hs-CRP (mg/L) 1.5±3.7 1.4±3.6 1.8±4.2 0.430 
CANHEART health index3
   Poor 342 (13.0) 323 (12.7) 19 (21.8) 0.040 
   Intermediate 1,520 (58.0) 1,477 (58.3) 43 (49.4) 
   Ideal 760 (29.0) 735 (29.0) 25 (28.7) 












Age (yr) 57.2±3.9 57.2±3.9 58.3±3.9 0.010 
Gender
   Men 830 (31.7) 818 (32.3) 12 (13.8) <0.001
   Women 1,792 (68.3) 1,717 (67.7) 75 (86.2) 
Educational attainment (yr)
   ≤6 218 (8.3) 192 (7.6) 26 (29.9) <0.001
   6-9 326 (12.4) 295 (11.6) 31 (35.6) 
   9-12 1,118 (42.6) 1,091 (43.0) 27 (31.0) 
   >12 960 (36.6) 957 (37.8) 3 (3.5) 
Family income (annual)
   Q1 653 (24.9) 612 (24.1) 41 (47.1) <0.001
   Q2 772 (29.4) 743 (29.3) 29 (33.3) 
   Q3 510 (19.5) 502 (19.8) 8 (9.2) 
   Q4 687 (26.2) 678 (26.8) 9 (10.3) 
Marital status
   Unmarried 27 (1.0) 27 (1.1) 0 (0.0) 0.330 
   Married
      Death of spouse 151 (5.8) 145 (5.7) 6 (6.9) 
      Separated 146 (5.6) 138 (5.4) 8 (9.2) 
      Living together 2,298 (87.6) 2,225 (87.8) 73 (83.9) 
Smoking
   Non-smoker 1,909 (72.8) 1,835 (72.4) 74 (85.1) 0.020 
   Former smoker 481 (18.3) 470 (18.5) 11 (12.6) 
   Current smoker 232 (8.9) 230 (9.1) 2 (2.3) 
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the analysis was performed. Total cholesterol, high-density lipo-
protein cholesterol, low-density lipoprotein cholesterol, and tri-
glyceride levels were measured enzymatically (ADVIA1800 Auto 
Analyzer, Siemens Medical Solutions). Fasting blood glucose lev-
els were measured with a colorimetric assay (ADVIA1800 Auto 
Analyzer, Siemens Medical Solutions). 
Height was measured to the nearest 0.1 cm with an optical lin-
ear encoder scale, and body weight was measured to the nearest 
0.1 kg on a digital scale. Body mass index (BMI) was calculated as 
weight divided by height squared (kg/m2). Upper arm blood pres-
sure was measured 3 times after the participant had been seated 
and at rest for at least 5 minutes. We utilized the average of the 
second and third blood pressure measurements.
Statistical analysis
The chi-square test and analysis of variance (F-test) were used 
to compare baseline differences in covariates of the MMSE-DS 
score categories (cut-off= 24). Continuous variables are shown as 
mean and standard deviation, while categorical variables are shown 
as frequency and percentage. A logistic regression model examined 
the association between the CVH level and cognitive dysfunction. 
The final model was adjusted for age [23], educational level [24], 
household income level [25], marital status [26], current drinking 
status [27], mean systolic blood pressure [28], total cholesterol [29], 
and fasting glucose level [30]. The selection of confounders was 
based on previous studies, and in the variance inflation factor (VIF) 
test for the detection of multicollinearity, all covariates included 
in the model satisfied the criterion (VIF< 10). Stratified analyses 
by hs-CRP level were conducted with the same covariates, and we 
used tertiles to classify the hs-CRP levels. Sensitivity analyses were 
conducted for comparison with pre-imported data using the same 
logistic regression model (n= 2,241), excluding participants who 
did not complete the dietary questionnaire. All statistical analyses 
were performed using SAS version 9.4 (SAS Institute Inc., Cary, 
NC, USA).
Ethics statement
All participants provided written informed consent, and the 
study protocol was approved by the Yonsei University College of 
Medicine Hospital Institutional Review Board (4-2013-0661). All 
procedures complied with the ethical standards of the relevant 
national and institutional committees on human experimentation 
as per the Helsinki Declaration of 1975 (revised in 2008).
RESULTS
The characteristics of the study participants (n = 2,622) are 
shown in Table 1. Men and women constituted 31.7% and 68.3% 
Table 2. Associations between the CANHEART health index and cognitive function by hs-CRP tertiles 
CANHEART health index1
Low cognitive function (MMSE-DS<24)2
p for trendAge and sex-adjusted 
model
Model 1, additionally adjusted 
for SES and drinking status
Model 2, additionally 
adjusted for health status
Total participants (n=2,622) 0.143
   Poor (n=342) 2.38 (1.28-4.42) 1.62 (0.86-3.03) 1.99 (1.01-3.92)
   Intermediate (n=1,520) 0.95 (0.58-1.57) 0.76 (0.46-1.26) 0.83 (0.50-1.38)
   Ideal (n=760) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Stratified analysis by hs-CRP
   Lower tertile -
      Poor (n=75) 5.05 (1.75, 14.53) 3.87 (1.32, 11.40) 3.46 (1.14, 10.45)
      Intermediate (n=472) 1.34 (0.57, 3.15) 1.06 (0.46, 2.45) 1.01 (0.44, 2.32)
      Ideal (n=321) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Middle tertile -
      Poor (n=109) 2.76 (0.97, 7.83) 1.82 (0.62, 5.33) 2.79 (0.84, 9.20)
      Intermediate (n=515) 0.64 (0.27, 1.49) 0.50 (0.21, 1.15) 0.57 (0.24, 1.35)
      Ideal (n=253) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Higher tertile -
      Poor (n=158) 1.32 (0.45, 3.89) 0.91 (0.31, 2.67) 1.21 (0.39, 3.78)
      Intermediate (n=533) 0.97 (0.39, 2.24) 0.74 (0.31, 1.75) 0.84 (0.35, 2.02)
      Ideal (n=186) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Values are presented as odds ratio (95% confidence interval). 
MMSE-DS, Mini-Mental State Examination-Dementia Screening; SES, socioeconomic status; SBP, systolic blood pressure; hs-CRP, high-sensitivity 
C-reactive protein.
1The CANHEART health index and its criteria defined by the Cardiovascular Health in Ambulatory Care Research Team in 2014.
2Results from a logistic regression model with the penalized likelihood option; model 1: age and sex-adjusted model+adjustment for household 
income, education level, marital status, and drinking status; model 2: model 1+adjustment for smoking status, total cholesterol, fasting glucose, 
and SBP.
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of the study group, respectively. The mean age of participants was 
57.2 years. Participants were classified by cognitive function as 
determined by the MMSE-DS score. Based on the MMSE-DS 
score, 2,535 participants were classified as having normal cogni-
tive function and 87 (3.3%) participants exhibited low cognitive 
function (MMSE-DS score < 24). Lower cognitive function scores 
were associated with older age, women, low education level, low 
family income, non-smoking, and poor CVH (p< 0.05).
CANHEART health index and cognitive function
Overall, poor CVH (evaluated by the CANHEART health in-
dex; poor= 0-1, intermediate= 2-5, and ideal= 6) was significant-
Table 3. Associations between the CANHEART health index and cognitive function in men and women by hs-CRP tertiles 
CANHEART health index1
Low cognitive function (MMSE-DS<24)2
P for trend
Age-adjusted model Model 1, additionally adjusted for SES and drinking status
Model 2, additionally 
adjusted for health status
Men (n=830)
   Total 0.037
      Poor (n=274) 8.25 (0.47, 145.40) 7.07 (0.56, 88.93) 9.33 (0.76, 14.13)
      Intermediate (n=279) 4.28 (0.25, 72.61) 4.62 (0.38, 55.90) 5.61 (0.49, 64.87)
      Ideal (n=277) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Stratified analysis by hs-CRP
      Lower tertile -
         Poor (n=41) 11.68 (0.64, 212.35) 9.06 (0.65, 126.07) 14.59 (0.94, 27.17)
         Intermediate (n=168) 1.95 (0.10, 37.46) 3.86 (0.27, 55.28) 5.40 (0.36, 80.16)
         Ideal (n=65) 1.00 (reference) 1.00 (reference) 1.00 (reference)
      Middle tertile -
         Poor (n=65) 0.50 (0.01, 23.13) 0.58 (0.03, 10.43) 0.83 (0.09, 7.39)
         Intermediate (n=166) 1.30 (0.07, 24.86) 1.74 (0.19, 16.00) 1.28 (0.22, 7.39)
         Ideal (n=48) 1.00 (reference) 1.00 (reference) 1.00 (reference)
      Higher tertile -
         Poor (n=78) 1.71 (0.08, 35.79) 1.15 (0.08, 17.34) 1.04 (0.08, 14.36)
         Intermediate (n=171) 1.12 (0.06, 21.60) 0.88 (0.06, 12.32) 0.86 (0.07, 10.55)
         Ideal (n=28) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Women (n=1,792)
   Total 0.485
      Poor (n=158) 2.37 (1.27, 4.45) 1.61 (0.84, 3.09) 2.03 (1.00, 4.11)
      Intermediate (n=1,015) 0.96 (0.58, 1.59) 0.76 (0.45, 1.28) 0.83 (0.49, 1.41)
      Ideal (n=619) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Stratified analysis by hs-CRP
      Lower tertile -
         Poor (n=24) 3.55 (1.03, 12.27) 2.81 (0.79, 9.96) 2.27 (0.62, 8.37)
         Intermediate (n=304) 1.26 (0.52, 3.02) 1.00 (0.43, 2.37) 0.93 (0.39, 2.20)
         Ideal (n=256) 1.00 (reference) 1.00 (reference) 1.00 (reference)
      Middle tertile -
         Poor (n=44) 3.36 (1.16, 9.67) 2.17 (0.70, 6.67) 3.44 (0.93, 12.73)
         Intermediate (n=349) 0.55 (0.22, 1.34) 0.38 (0.15, 0.95) 0.43 (0.17, 1.10)
         Ideal (n=205) 1.00 (reference) 1.00 (reference) 1.00 (reference)
      Higher tertile -
         Poor (n=80) 1.15 (0.35, 3.82) 0.81 (0.25, 2.69) 1.16 (0.32, 4.17)
         Intermediate (n=362) 0.87 (0.35, 2.13) 0.68 (0.28, 1.68) 0.81 (0.32, 2.04)
         Ideal (n=158) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Values are presented as odds ratio (95% confidence interval).
MMSE-DS, Mini-Mental State Examination-Dementia Screening; SES, socioeconomic status; SBP, systolic blood pressure; hs-CRP, high-sensitivity 
C-reactive protein.
1The CANHEART health index and its criteria defined by the Cardiovascular Health in Ambulatory Care Research Team in 2014.
2Results from a logistic regression model with the penalized likelihood option; model 1: age-adjusted model+adjustment for household income, 
education level, marital status, and drinking status; model 2: model 1+adjustment for total cholesterol, fasting glucose, and SBP.
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Table 4. Associations between each CANHEART health index component and cognitive function in men and women by hs-CRP tertiles 
(n=830)






   Smoking
      Current smoker (n=233) 0.70 (0.23, 2.09) 1.01 (0.19, 0.30) 0.65 (0.14, 3.01) 0.59 (0.14, 2.41)
      Non-smoker or former (n=597) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Overweight, obesity (kg/m2)
      BMI≥25 (n=366) 1.31 (0.49, 0.49) 3.37 (0.80, 14.26) 1.00 (0.25, 3.97) 1.27 (0.34, 4.78)
      BMI<25 (n=464) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Leisure physical activity (min/d)
      <30 (n=218) 1.27 (0.45, 3.57) 0.52 (0.09, 3.02) 0.73 (0.15, 3.62) 2.47 (0.68, 9.04)
      ≥30 (n=612) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Fruit and vegetable consumption (servings/d)
      <5 (n=241) 2.04 (0.75, 5.53) 0.96 (0.21, 4.47) 1.49 (0.37, 5.97) 3.83 (0.91, 16.13)
      ≥5 (n=589) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Hypertension3
      Yes (n=240) 3.79 (1.29, 11.10) 7.68 (1.66, 35.59) 0.88 (0.18, 4.30) 1.37 (0.35, 5.34)
      No (n=590) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Diabetes3
      Yes (n=87) 1.73 (0.37, 8.23) 4.81 (0.47, 49.71) 4.40 (0.80, 24.15) 0.55 (0.04, 8.33)
      No (n=743) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Women 
   Smoking
      Current smoker (n=26) 0.25 (0.02, 4.27) 0.92 (0.04, 23.50) 1.51 (0.08, 29.72) 0.26 (0.01, 5.99)
      Non-smoker or former (n=1,766) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Overweight, obesity (kg/m2)
      BMI≥25 (n=520) 1.28 (0.78, 2.11) 2.05 (0.86, 4.88) 0.96 (0.41, 2.24) 1.25 (0.56, 2.81)
      BMI<25 (n=1,272) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Leisure physical activity (min/d)
      <30 (n=487) 1.02 (0.60, 1.73) 0.98 (0.40, 2.36) 1.03 (0.40, 2.65) 1.30 (0.55, 3.06)
      ≥30 (n=1,305) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Fruit and vegetable consumption (servings/d) 
      <5 (n=370) 1.44 (0.85, 2.44) 1.43 (0.58, 3.52) 2.52 (1.06, 6.00) 0.89 (0.35, 2.28)
      ≥5 (n=1,422) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Hypertension3
      Yes (n=364) 0.93 (0.52, 1.65) 1.37 (0.54, 3.49) 0.65 (0.22, 1.92) 0.84 (0.34, 2.10)
      No (n=1,428) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
   Diabetes3
      Yes (n=97) 1.40 (0.51, 3.86) 0.43 (0.05, 4.05) 4.12 (0.80, 21.12) 1.32 (0.27, 6.53)
      No (n=1,695) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Values are presented as odds ratio (95% confidence interval).
MMSE-DS, Mini-Mental State Examination-Dementia Screening; BMI, body mass index; OR, odds ratio; CI, confidence interval; SBP, systolic blood 
pressure; hs-CRP, high-sensitivity C-reactive protein.
1The CANHEART health index and its criteria defined by the Cardiovascular Health in Ambulatory Care Research Team in 2014.
2Results from a logistic regression model with the penalized likelihood option, adjusted for age, education level, household income, marital status, 
current drinking status, total cholesterol, fasting glucose level, and mean SBP.
3Self-reported disease history (lifetime).
ly associated with low cognitive function (evaluated by the 
MMSE-DS, score < 24) after full adjustment (odds ratio [OR], 
1.99; 95% confidence interval [CI], 1.01 to 3.92) (Table 2). We ad-
ditionally checked linearity with the same model, but it was not 
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significant (ptrend = 0.143). The association between CVH and cog-
nitive decline in men is presented in Table 3; compared to ideal 
CVH, poor CVH was associated with low cognitive function, with 
an OR of 9.33, although this association was not significant. The 
linear association between CVH and low cognitive function was 
significant (ptrend = 0.037). In the subgroup analysis by hs-CRP 
tertiles, only the lower tertile showed a significant association be-
tween CVH and cognitive function, and the effect size was strong 
(hs-CRP lower tertile: OR, 3.46; 95% CI, 1.14 to 10.45). In the strat-
ified analysis conducted across hs-CRP tertiles, the risk of cogni-
tive decline was highest in the group with high hs-CRP levels and 
poor CVH, although this relationship was not statistically signifi-
cant. The associations between CVH and cognitive decline in wom-
en are presented in Table 3. Compared to the ideal CANHEART 
health index, poor CVH was associated with low cognitive func-
tion in women, with an OR of 2.03 (95% CI, 1.00 to 4.11). 
The risk of cognitive decline was highest in those with an inter-
mediate hs-CRP level and poor CVH, but this relationship was 
not significant. In a previous analysis conducted in the same pop-
ulation, we assessed the association between the AHA Life’s Sim-
ple 7 score (poor, 0-2; intermediate, 3-4; ideal; 5-7) and cognitive 
decline. Poor CVH measured by the AHA Life’s Simple 7 score 
was positively associated with low cognitive function compared 
to ideal CVH, but this relationship was not statistically significant 
in either men or women (Supplementary Material 2; men: OR; 
1.71; 95% CI, 0.37 to 7.93; women: OR, 1.20; 95% CI, 0.55 to 2.58). 
For sensitivity analyses, we conducted the same analyses in pre-
imputed data for dietary intake (n= 2,241); the characteristics of 
included and excluded participants are presented in Supplemen-
tary Material 3. Overall, the association between poor CVH and 
low cognitive function was strong in the lower hs-CRP tertile 
(Supplementary Material 4).
Components of the CANHEART health index and 
cognitive function
The associations of each component of CANHEART health 
index, including current smoking status, overweight status, leisure 
physical activity, fruit and vegetable consumption, hypertension, 
and diabetes, with cognitive decline in men are presented in Table 
4. Low cognitive function was only associated with hypertension 
in men, with an OR of 3.79 (95% CI, 1.29 to 11.10). A definite as-
sociation between hypertension and low cognitive function was 
represented in those with high hs-CRP levels, with an OR of 7.68 
(95% CI, 1.66 to 35.59). In women, there was no significant asso-
ciation between the CANHEART health index components and 
low cognitive function (Table 4). 
 
DISCUSSION
The association between CVH and early cognitive function was 
not significant, and the level of hs-CRP did not affect the risk of 
cognitive dysfunction. The CVH assessment results obtained us-
ing the CANHEART health index did not show an association 
with cognitive function in either men or women, except in wom-
en with poor CVH scores. A stratified analysis across hs-CRP ter-
tiles revealed no mediatory effect in the relationship between CVH 
and cognitive function. Although the presence of hypertension in 
men was associated with cognitive dysfunction, no other compo-
nent of CVH had a significant association with cognition in either 
men or women. 
Many previous studies have suggested that poor CVH is associ-
ated with cognitive decline. According to prospective cohort stud-
ies conducted in the United Kingdom, dementia incidence among 
participants with a low CVH level evaluated by the AHA Life’s 
Simple 7 tool was approximately twice as high as that of normal 
participants. Inflammation levels have also been speculated to play 
a role in modifying the association between CVH and cognitive 
function. Low-grade chronic inflammation can increase the risk of 
atherosclerosis and insulin resistance, which are the leading mech-
anisms in the development of cardiovascular disease [31]. Com-
bined inflammation was significantly associated with memory and 
psychomotor speed. Moreover, chronic inflammation results in an 
increase in cytokine levels, causing hypersecretion of cortisol. In-
creased steroid levels reduce the synthesis of neurotrophic factors and 
prevent the repair of damaged neuronal networks. Furthermore, 
data from a cohort study of Japanese-American men showed that 
high levels of hs-CRP increased the risk of all types of dementia [14].
Our study presented different results from those of previous 
studies. We found that CVH levels did not show an association 
with early cognitive decline in our study population. The current 
study also confirmed that inflammation levels had no significant 
association with cognitive dysfunction. Several explanations for 
these differences could be suggested. Since the study population 
was only in an early stage of cognitive impairment, not the stage 
of dementia, the influence of CVH and inflammatory status on 
cognitive decline could be weak [32]. Since the criterion in previ-
ous studies was dementia, the results of those studies could be 
different from ours [7,8]. This possibility is supported by some 
findings suggesting that CRP levels could be different in different 
stages of disease [33]. In addition, variations across different co-
horts could provide an explanation. Reportedly, the fruit and veg-
etable consumption in Korea is about 377.0 g/d [34], whereas that 
in France is 342 g/d and that in the United Kingdom is 258 g/d 
[35]. Since a comparatively high consumption of fruits and vege-
tables could contribute to a delay in cognitive decline, the effects 
of CVH and hs-CRP could be masked [36]. It is also possible that 
unknown differences in Eastern/Western population health-relat-
ed factors might have an effect. Differences in the methods of 
measuring cognitive dysfunction could be another reason for in-
consistent study outcomes. In our study, the Korean version of the 
MMSE-DS was used, whereas previous studies used a combina-
tion of cognitive tests [7]. The differences between the AHA’s Life’s 
Simple 7 tool and the CANHEART model might also cause dis-
similar results. The AHA’s Life’s Simple 7 tool includes smoking, 
physical activity, healthy diet, BMI, total cholesterol, blood pres-
sure, and fasting plasma glucose [19]. In comparison, the CAN-
Epidemiol Health 2021;43:e2021044
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HEART index includes smoking, leisure physical activity, fruit 
and vegetable consumption, BMI, hypertension, and diabetes; 
several of these components are subjective and may be easily af-
fected by recall bias [37]. The total cholesterol level was also ex-
cluded from CANHEART components. Due to this difference in 
CVH measurements, our findings may differ from those of previ-
ous studies. To compare the CANHEART health index and the 
AHA Life’s Simple 7 tool, we estimated the association between 
the AHA Life’s Simple 7 tool and cognitive function; as shown in 
Supplementary Material 2, the confidence interval for the ORs 
was wider with the CANHEART health index.
According to our knowledge, this is the first investigation to as-
sess the association between the CANHEART health index and 
cognitive function in Korean population; as such, our results are 
meaningful. However, the current study had several limitations. 
First, there was a small number of participants with low cognitive 
function. In this study, only 87 of the 2,622 participants had an 
MMSE-DS score below 24. The smaller sample size than previous 
studies may compromise the statistical power of the current study, 
as the post-hoc power of the current analysis was found to be 
about 55.6% (n= 2,622). A previous research study conducted in 
France included 745 dementia patients in a total study population 
of 6,626 [8]. Another study conducted in the United Kingdom in-
cluded 347 dementia patients in a total population of 7,899 [7]. 
Second, the CANHEART model used for measuring CVH was 
originally designed by Canadian researchers, meaning that its va-
lidity is unknown for the Korean population. Third, our study 
had a cross-sectional design; therefore, the temporal association 
between CVH and cognitive function could not be verified. Fourth, 
the elements that may have caused conflicting results in studies 
investigating associations between CVH and cognitive function 
in different populations are unknown. Several factors such as ge-
netic differences between races [38], the degree of fruit and vege-
table consumption [39,40], or environmental and cultural influ-
ences [41] could be relevant. Further investigations to develop an 
appropriate index for the Korean population are needed.
Our study found that poor CVH levels showed a non-signifi-
cant association with early cognitive decline, and inflammation 
levels did not have a modifying effect on this relationship. Several 
recommendations can be made for designing future studies to as-
certain why our results conflicted with those of previous studies. 
A larger study population would be important, since in our study, 
the small size of the study group may have been the reason for 
non-significance. The measurement of other peripheral inflam-
matory factors, such as interleukin-6 or tumor necrosis factor-al-
pha, could be recommended instead of hs-CRP. Comparing early 
cognitive decline with late stages of cognitive decline, such as AD, 
would also be needed in further studies. 
SUPPLEMENTARY MATERIALS
Supplementary materials are available at http://www.e-epih.
org/.
CONFLICT OF INTEREST
The authors have no conflicts of interest to declare for this 
study.
FUNDING
This research was supported by Basic Science Research Pro-
gram through the National Research Foundation of Korea (NRF) 
funded by the Ministry of Science and ICT (2020R1C1C1003502) 
and a faculty research grant of Yonsei University College of Medi-
cine for 2019 (6-2019-0114).
ACKNOWLEDGEMENTS
We would like to thank J. Kim for statistical advice.
AUTHOR CONTRIBUTIONS
Conceptualization: SJJ. Data curation: SJJ, YJJ. Formal analysis: 
YJJ. Funding acquisition: SJJ, HCK. Methodology: YJJ. Writing –
original draft: JHL, YJJ. Writing – review & editing: SJJ, HCK YJJ.
ORCID
Ye Jin Jeon: https://orcid.org/0000-0002-3780-5668; Ji Heon Lee: 
https://orcid.org/0000-0002-7511-3371; Hyeon Chang Kim: https:// 
orcid.org/0000-0001-7867-1240; Sun Jae Jung: https://orcid.org/ 
0000-0002-5194-7339
REFERENCES
1. Kim YJ, Han JW, So YS, Seo JY, Kim KY, Kim KW. Prevalence 
and trends of dementia in Korea: a systematic review and meta-
analysis. J Korean Med Sci 2014;29:903-912.
2. Brodaty H, Hadzi-Pavlovic D. Psychosocial effects on carers of 
living with persons with dementia. Aust N Z J Psychiatry 1990; 
24:351-361.
3. Leifer BP. Early diagnosis of Alzheimer’s disease: clinical and eco-
nomic benefits. J Am Geriatr Soc 2003;51(5 Suppl Dementia): 
S281-S288.
4. Weller J, Budson A. Current understanding of Alzheimer’s disease 
diagnosis and treatment. F1000Res 2018;7:F1000 Faculty Rev-
1161.
5. Doraiswamy PM, Krishnan KR, Anand R, Sohn H, Danyluk J, 
Hartman RD, et al. Long-term effects of rivastigmine in moder-
ately severe Alzheimer’s disease: does early initiation of therapy 
offer sustained benefits? Prog Neuropsychopharmacol Biol Psy-
chiatry 2002;26:705-712.
6. Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis 
K, et al. Strategic roadmap for an early diagnosis of Alzheimer’s 
disease based on biomarkers. Lancet Neurol 2017;16:661-676.
7. Sabia S, Fayosse A, Dumurgier J, Schnitzler A, Empana JP, Eb-
Jeon YJ et al. : CVH, inflammation, and cognition
www.e-epih.org    |  9
meier KP, et al. Association of ideal cardiovascular health at age 
50 with incidence of dementia: 25 year follow-up of Whitehall II 
cohort study. BMJ 2019;366:l4414.
8. Samieri C, Perier MC, Gaye B, Proust-Lima C, Helmer C, Dart-
igues JF, et al. Association of cardiovascular health level in older 
age with cognitive decline and incident dementia. JAMA 2018; 
320:657-664.
9. Chi GC, Fitzpatrick AL, Sharma M, Jenny NS, Lopez OL, DeKo-
sky ST. Inflammatory biomarkers predict domain-specific cogni-
tive decline in older adults. J Gerontol A Biol Sci Med Sci 2017; 
72:796-803.
10. Clearfield MB. C-reactive protein: a new risk assessment tool for 
cardiovascular disease. J Am Osteopath Assoc 2005;105:409-416.
11. Cook NR, Buring JE, Ridker PM. The effect of including C-reac-
tive protein in cardiovascular risk prediction models for women. 
Ann Intern Med 2006;145:21-29.
12. Bruunsgaard H. Physical activity and modulation of systemic low-
level inflammation. J Leukoc Biol 2005;78:819-835.
13. Rubinow DR, Post RM, Savard R, Gold PW. Cortisol hypersecre-
tion and cognitive impairment in depression. Arch Gen Psychia-
try 1984;41:279-283.
14. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger 
JA. Association of C-reactive protein with cognitive impairment. 
Arch Neurol 2010;67:87-92.
15. Song IU, Chung SW, Kim YD, Maeng LS. Relationship between 
the hs-CRP as non-specific biomarker and Alzheimer’s disease 
according to aging process. Int J Med Sci 2015;12:613-617.
16. Wersching H, Duning T, Lohmann H, Mohammadi S, Stehling C, 
Fobker M, et al. Serum C-reactive protein is linked to cerebral 
microstructural integrity and cognitive function. Neurology 2010; 
74:1022-1029.
17. Folsom AR, Shah AM, Lutsey PL, Roetker NS, Alonso A, Avery 
CL, et al. American Heart Association’s Life’s Simple 7: avoiding 
heart failure and preserving cardiac structure and function. Am J 
Med 2015;128:970-976.e2.
18. Jeon YJ, Jung SJ, Kim HC. Does serum vitamin D level affect the 
association between cardiovascular health and cognition? Results 
of the Cardiovascular and Metabolic Diseases Etiology Research 
Center (CMERC) study. Eur J Neurol 2021;28:48-55.
19. Maclagan LC, Park J, Sanmartin C, Mathur KR, Roth D, Manuel 
DG, et al. The CANHEART health index: a tool for monitoring 
the cardiovascular health of the Canadian population. CMAJ 
2014;186):180-187.
20. Shim JS, Song BM, Lee JH, Lee SW, Park JH, Choi DP, et al. Car-
diovascular and Metabolic Diseases Etiology Research Center 
(CMERC) cohort: study protocol and results of the first 3 years of 
enrollment. Epidemiol Health 2017;39:e2017016.
21. Kim TH, Jhoo JH, Park JH, Kim JL, Ryu SH, Moon SW, et al. Ko-
rean version of mini mental status examination for dementia 
screening and its’ short form. Psychiatry Investig 2010;7:102-108.
22. Chun MY. Validity and reliability of Korean version of internation-
al physical activity questionnaire short form in the elderly. Kore-
an J Fam Med 2012;33:144-151.
23. Sato N. Aging and dementia. Nihon Rinsho 2016;74:1518-1525 
(Japanese).
24. Lövdén M, Fratiglioni L, Glymour MM, Lindenberger U, Tucker-
Drob EM. Education and cognitive functioning across the life 
span. Psychol Sci Public Interest 2020;21:6-41.
25. Lee S, Buring JE, Cook NR, Grodstein F. The relation of education 
and income to cognitive function among professional women. 
Neuroepidemiology 2006;26:93-101.
26. Liu H, Zhang Y, Burgard SA, Needham BL. Marital status and 
cognitive impairment in the United States: evidence from the 
National Health and Aging Trends Study. Ann Epidemiol 2019; 
38:28-34.e2.
27. Koch M, Fitzpatrick AL, Rapp SR, Nahin RL, Williamson JD, 
Lopez OL, et al. Alcohol consumption and risk of dementia and 
cognitive decline among older adults with or without mild cogni-
tive impairment. JAMA Netw Open 2019;2:e1910319.
28. Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley 
W, et al. Association of blood pressure lowering with incident de-
mentia or cognitive impairment: a systematic review and meta-
analysis. JAMA 2020;323:1934-1944.
29. Panza F, Capurso C, D’Introno A, Colacicco AM, De Candia D, 
Capurso A, et al. Total cholesterol levels and the risk of mild cog-
nitive impairment and Alzheimer’s disease. J Am Geriatr Soc 
2007;55:133-135.
30. Xue M, Xu W, Ou YN, Cao XP, Tan MS, Tan L, et al. Diabetes 
mellitus and risks of cognitive impairment and dementia: a sys-
tematic review and meta-analysis of 144 prospective studies. Age-
ing Res Rev 2019;55:100944.
31. von Hundelshausen P, Weber C. Chronic inflammation and ath-
erosclerosis. Dtsch Med Wochenschr 2013;138:1839-1844 (Ger-
man).
32. Yarchoan M, Louneva N, Xie SX, Swenson FJ, Hu W, Soares H, et 
al. Association of plasma C-reactive protein levels with the diag-
nosis of Alzheimer’s disease. J Neurol Sci 2013;333:9-12.
33. Fernandes A, Tábuas-Pereira M, Duro D, Lima M, Gens H, San-
tiago B, et al. C-reactive protein as a predictor of mild cognitive 
impairment conversion into Alzheimer’s disease dementia. Exp 
Gerontol 2020;138:111004.
34. Korea Centers for Disease Control and Prevention. Korea health 
statistics 2018: Korea National Health and Nutrition Examination 
Survey (KNHANES VII-3); 2019. Available from: https://knhanes. 
kdca.go.kr/knhanes/sub04/sub04_04_01.do (Korean)
35. Elmadfa I, Meyer A, Nowak V, Hasenegger V, Putz P, Verstraeten 
R, et al. European nutrition and health report 2009. Forum Nutr 
2009;62:1-405.
36. Głąbska D, Guzek D, Groele B, Gutkowska K. Fruit and vegetable 
intake and mental health in adults: a systematic review. Nutrients 
2020;12:115.
37. Crump K. The potential effects of recall bias and selection bias on 
the epidemiological evidence for the carcinogenicity of glyphosate. 
Risk Anal 2020;40:696-704.
38. Hackler E 3rd, Lew J, Gore MO, Ayers CR, Atzler D, Khera A, et 
al. Racial differences in cardiovascular biomarkers in the general 
Epidemiol Health 2021;43:e2021044
  |    www.e-epih.org  10
population. J Am Heart Assoc 2019;8:e012729.
39. Stearns JC, Zulyniak MA, de Souza RJ, Campbell NC, Fontes M, 
Shaikh M, et al. Ethnic and diet-related differences in the healthy 
infant microbiome. Genome Med 2017;9:32.
40. Li W, Youssef G, Procter-Gray E, Olendzki B, Cornish T, Hayes R, 
et al. Racial differences in eating patterns and food purchasing 
behaviors among urban older women. J Nutr Health Aging 2017; 
21:1190-1199.
41. Lee CY, Lee YH. Measurement of socioeconomic position in re-
search on cardiovascular health disparities in Korea: a systematic 
review. J Prev Med Public Health 2019;52:281-291.
